Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

This trial is testing the combination of amivantamab (a targeted antibody drug) plus a single chemotherapy drug for people with a specific type of non-small cell lung cancer (NSCLC) caused by an EGFR exon 20 insertion mutation, who are not able to tolerate platinum-based chemotherapy. **You may be eligible if...** - You are 18 or older - You have stage IV or recurrent non-squamous non-small cell lung cancer with an EGFR exon 20 insertion mutation (confirmed by genetic testing) - You have not received any prior systemic treatment for this cancer - You are not suitable for platinum-based chemotherapy (due to poor kidney function, age over 80, neurological problems, or allergy to platinum) - You have at least one measurable tumor **You may NOT be eligible if...** - You have already received systemic treatment for this lung cancer - You can tolerate platinum-based chemotherapy - You have uncontrolled or symptomatic brain metastases - You have serious heart, liver, or autoimmune problems Talk to your doctor to see if this trial is right for you.